Cart
sales@molnova.com
Sevoflurane
CAS No. 28523-86-6
Sevoflurane( Fluoromethyl )
Catalog No. M27577 CAS No. 28523-86-6
Sevoflurane, a noncompetitive inhibitor of 5-HT3 receptor, acts as a low-soluble inhalation anesthetics.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 41 | In Stock |
|
| 10MG | 58 | In Stock |
|
| 25MG | 102 | In Stock |
|
| 50MG | 151 | In Stock |
|
| 100MG | 227 | In Stock |
|
| 200MG | 339 | In Stock |
|
| 500MG | 570 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSevoflurane
-
NoteResearch use only, not for human use.
-
Brief DescriptionSevoflurane, a noncompetitive inhibitor of 5-HT3 receptor, acts as a low-soluble inhalation anesthetics.
-
DescriptionSevoflurane, a noncompetitive inhibitor of 5-HT3 receptor, acts as a low-soluble inhalation anesthetics.
-
In Vitro——
-
In Vivo——
-
SynonymsFluoromethyl
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number28523-86-6
-
Formula Weight200.05
-
Molecular FormulaC4H3F7O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESFCOC(C(F)(F)F)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chutrakul C, et al. Metabolic engineering of long chain-polyunsaturated fatty acid biosynthetic pathway in oleaginous fungus for dihomo-gamma linolenic acid production. J Biotechnol. 2016;218:85-93.
molnova catalog
related products
-
Targocil
Targocil is used as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) (MIC90s: 2 μg/ mL) for both MRSA and MSSA.
-
Mebhydrolin napadisy...
Mebhydrolin (napadisylate) is an antihistamine, used for symptomatic relief of allergic symptoms caused by histamine release.
-
Clomipramine hydroch...
Clomipramine HCl is a serotonin transporter (SERT).
